Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
Bit more than a wristband...Cloudtag’s current commercial focus and use of the platform is SaaS service charged per patient which will be able to remotely diagnose the individual’s nutritional & physical outputs with 2 primary aims:
– Pre surgical procedure: getting the individual into the weight range they need to be in order to receive the reimbursement from the insurance company private/government. This platform will be used for pre and post-surgical intervention and,
– Individuals who are on preventive programme – reducing their propensity for attracting Type 2 diabetes with continual monitoring of the individual’s trajectory against the pre-determined map.
Furthermore, the platform has created a more holistic product (SaaS tool) that will monitor an individual’s physical activity utilising, primarily, raw HR and VHR outputs (from known 3rd party devices) which will be filtered through our proprietary software and augmented with other physiological outputs such as blood pressure, glucose level, urine PH. Further new addition to the platform is inputs are from a data-controlled food and proprietary health digital sensor that gathers personal health data. This information is translated into personalised physical & nutritional advice that contributes to a healthier lifestyle, or that is adapted to specific situations such as weight reduction programme or hospital admission.
The platform’s impact on society is a vast one spanning from the reduction of the number of people who need to undergo surgical interventions with its possible post-complications, reduction in use of drugs & their side effects, reducing social care & direct & indirect health care costs and on the other hand bringing increasing productivity and improving quality of life.
Seethruwalls Agree, does seem unlikely, but maybe Amit does not ever look at the site, if he gave in years ago, It was just that I looked at all the posts, all are in good grammar and correct spelling, until the commercial update, and most since, are poorly written! who knows?
Carados, can you shed any light on the tweet... it does not now seem to have been sent by Amit, I too am beginning to think some sicko has hacked the website!
So that twitter tweet was false?
It is an illusion, spread over 30% and MMs only offering 0.017 to sell
35 mins to Nasdaq opening!
Have to agree AIM4, unless something has changed and HL have received info from ABH, I contacted them with a few questions way back, after the first message from CTag, and their response was... We're aware of the announcement made by Cloudtag regarding a payment to shareholders.
Unfortunately, we would not be able to lodge your Cloudtag share certificates into your Fund & Share Account as the stock remains delisted. We'd only be able to accept the certificate if the stock relisted on an recognised exchange. your SIPP shares have remained in your SIPP account. Your ISA shares were moved to a trading account. We can take no further action, until notified directly by Cloudtag, or the shares are r-listed.
If you have any other questions, please get back to me.
What a windfall for them! but does show confidence and probably averts a cash call... good news
So no one knows anything! some saying never one saying a dickie bird told him late this week. seems we just wait for the sixth, and all will be revealed...or will it...just be so glad when this is over, and at this point I could not care which way it goes, but another delay, and I for one will give up!
While we wait, this adds credence, it shows he does know what he is doing, even if the way he does it, may not be what we like.
Biosense, which deals in development and production of medical equipment, was set up in 1993 by Professor Shlomo Ben-Haim, a tenured lecturer at the Technion medical school, and a visiting professor at Harvard University. Ben-Haim, who holds 19% of the shares in Biosense, will receive shares worth some $75 million. His brother, Adv. Amit Ben-Haim, who was the first investor in the company, holds 22% of the shares, and will receive Johnson & Johnson shares worth some $88 million.“
This is what got me interested when I discovered that it was Amit Ben-Haim was CEO of a small cap AIM company, CloudTag INC. After more digging I discovered that in 1996, he co-established Impulse Dynamics Inc., another medical devices company, which ultimately licensed its cardiac contractility technology to NYSE-listed Guidant Corporation (a group company of Boston Scientific) So unless he has been on the mother of all spending sprees, I guess he has a few bob left...